FXR-/- mice display both impaired glucose tolerance and decreased insulin sensitivity, therefore, the findings suggest that FXR activity can be a potential biomarker of the development and treatment of metabolic syndrome and T2D. This evidence concerns the gene INS and type 2 diabetes mellitus.